KemPharm's SDX Higher Dose Shows Potential Against Sleep Disorders

KemPharm Inc KMPH completed its analysis of the full data set from its Phase 1 clinical trial of serdexmethylphenidate (SDX) delivered at doses higher than those previously studied. 

  • SDX, KemPharm's proprietary prodrug of d-methylphenidate (d-MPH), is the sole active pharmaceutical ingredient (API) in KP1077, under development for idiopathic hypersomnia (IH).
  • The full data set built on the previously reported topline data affirmed that 240 mg and 360 mg doses of SDX were well-tolerated and produced d-MPH exposure that appeared to increase proportionally with dose. 
  • Mean d-MPH plasma concentrations gradually increased after SDX administration, reaching a broad peak from eight to twelve hours post-dose, followed by a shallow decline. 
  • Study participants reported increased wakefulness, alertness, hypervigilance, and insomnia effects.
  • KemPharm anticipates filing an Investigational New Drug (IND) application for KP1077 as early as Q2 of 2022 and subsequently initiating a Phase 2 trial in patients with IH in 2H of 2022. 
  • Additionally, the Company expects to receive results from an additional trial to assess the relative cardiovascular safety of SDX vs. current stimulant treatments also in 2H of 2022.
  • Price Action: KMPH shares are down 1.87% at $5.25 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!